These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18043689)

  • 21. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
    Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
    J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters.
    Kurokawa J; Sasano T; Kodama M; Li M; Ebana Y; Harada N; Honda S; Nakaya H; Furukawa T
    J Toxicol Sci; 2015 Jun; 40(3):339-48. PubMed ID: 25972195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
    Duncan RS; McPate MJ; Ridley JM; Gao Z; James AF; Leishman DJ; Leaney JL; Witchel HJ; Hancox JC
    Biochem Pharmacol; 2007 Aug; 74(3):425-37. PubMed ID: 17560554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition.
    Fossa AA; Wisialowski T; Magnano A; Wolfgang E; Winslow R; Gorczyca W; Crimin K; Raunig DL
    J Pharmacol Exp Ther; 2005 Jan; 312(1):1-11. PubMed ID: 15306635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
    Zünkler BJ; Wos-Maganga M
    Cardiovasc Toxicol; 2010 Sep; 10(3):161-5. PubMed ID: 20467834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.
    Wolpert C; Schimpf R; Giustetto C; Antzelevitch C; Cordeiro J; Dumaine R; Brugada R; Hong K; Bauersfeld U; Gaita F; Borggrefe M
    J Cardiovasc Electrophysiol; 2005 Jan; 16(1):54-8. PubMed ID: 15673388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
    Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
    Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839.
    Sparve E; Quartino AL; Lüttgen M; Tunblad K; Gårdlund AT; Fälting J; Alexander R; Kågström J; Sjödin L; Bulgak A; Al-Saffar A; Bridgland-Taylor M; Pollard C; Swedberg MD; Vik T; Paulsson B
    J Pharmacol Exp Ther; 2014 Aug; 350(2):469-78. PubMed ID: 24917547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition.
    Lin C; Ke X; Ranade V; Somberg J
    Cardiology; 2008; 110(3):145-52. PubMed ID: 18057881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
    Jo SH; Hong HK; Chong SH; Choe H
    Life Sci; 2008 Jan; 82(5-6):331-40. PubMed ID: 18191158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of the selective alphalA-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction.
    Tatemichi S; Kiguchi S; Kobayashi M; Yamazaki Y; Shibata N; Uruno T
    Arzneimittelforschung; 2006; 56(10):682-7. PubMed ID: 17225563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-undulant T-U-wave, sinus bradycardia and long QT syndrome: a possible phenotype of mutant genes controlling the inward potassium rectifiers.
    Shen CT; Wu YC; Yu SS; Wang NK
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1997; 38(4):267-75. PubMed ID: 9297927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart.
    Monassier L; Manoury B; Bellocq C; Weissenburger J; Greney H; Zimmermann D; Ehrhardt JD; Jaillon P; Baró I; Bousquet P
    J Pharmacol Exp Ther; 2007 Jul; 322(1):341-50. PubMed ID: 17460149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G
    Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QTc interval prolongation in patients on long-term methadone maintenance therapy.
    Maremmani I; Pacini M; Cesaroni C; Lovrecic M; Perugi G; Tagliamonte A
    Eur Addict Res; 2005; 11(1):44-9. PubMed ID: 15608471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
    Rampe D; Murawsky MK; Grau J; Lewis EW
    J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
    Meyers KM; Méndez-Andino JL; Colson AO; Warshakoon NC; Wos JA; Mitchell MC; Hodge KM; Howard JM; Ackley DC; Holbert JK; Mittelstadt SW; Dowty ME; Obringer CM; Reizes O; Hu XE
    Bioorg Med Chem Lett; 2007 Feb; 17(3):819-22. PubMed ID: 17107796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
    Wen D; Liu A; Chen F; Yang J; Dai R
    J Appl Toxicol; 2012 Oct; 32(10):834-42. PubMed ID: 22744888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.